Immunotherapy for early-stage cutaneous squamous cell carcinoma
Andrea Boutros, Yu-Ju Kuo, Alexander Maxwell Menzies, Georgina V Long, Francesco Spagnolo, Ines Pires da Silva · 2026
Read Immunotherapy for early-stage cutaneous squamous cell carcinoma by Andrea Boutros, Yu-Ju Kuo, Alexander Maxwell Menzies, Georgina V Long, Francesco Spagnolo, Ines Pires da Silva (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218093.txt.
Description
Andrea Boutros and co-authors review immunotherapy for early-stage cutaneous squamous cell carcinoma in a 2026 paper. Skin cancers of this type are common and rising, especially in older and immunosuppressed people, and most early cases are cured by surgery alone. Some carry high-risk features or sit where surgery is difficult, and immune checkpoint inhibitors are now being tested around surgery in such patients.
Trials of treatment given before surgery, using drugs such as cemiplimab and pembrolizumab, report high rates of major or complete tumor shrinkage, often above half. Results after surgery are mixed: one large trial of pembrolizumab was negative, while another improved disease-free survival without improving overall survival. The authors argue that staging systems poorly capture tumor biology and ignore immune suppression. They call for response-adapted trials that scale surgery, radiation, and drug therapy to each tumor, with broader entry for immunosuppressed patients.
Catalog record
| CREATOR | Andrea Boutros, Yu-Ju Kuo, Alexander Maxwell Menzies, Georgina V Long, Francesco Spagnolo, Ines Pires da Silva |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |